Corvus Pharmaceuticals presented preclinical data from its Phase1/1b study of CPI-444, and preliminary biomarker data from the trial.
The presentations took place Sept. 25 in New York City at the Second
CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating
Science into Survival as both oral and poster presentations.
The CPI-444 study looks at the drug as a single agent as
well as combined with Genentech’s TECENTRIQ.
The title of the presentation was “CPI-444: A potent and
selective inhibitor of A2AR induces antitumor responses alone and in
combination with anti-PD-L1 in preclinical and clinical studies.” Giving the
presentation was Corvus Senior Scientist Stephen Willingham.
Corvus presents CRP-444 data in oral and poster formats
Alerts Sign-up